Xylem R&D decreased by 6.7% to $56.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $56.00M to $56.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 2.6% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $53.00M | $49.00M | $52.00M | $52.00M | $53.00M | $47.00M | $54.00M | $53.00M | $58.00M | $61.00M | $60.00M | $59.00M | $58.00M | $55.00M | $58.00M | $56.00M | $58.00M | $52.00M | $60.00M | $56.00M |
| QoQ Change | — | -7.5% | +6.1% | +0.0% | +1.9% | -11.3% | +14.9% | -1.9% | +9.4% | +5.2% | -1.6% | -1.7% | -1.7% | -5.2% | +5.5% | -3.4% | +3.6% | -10.3% | +15.4% | -6.7% |
| YoY Change | — | — | — | — | +0.0% | -4.1% | +3.8% | +1.9% | +9.4% | +29.8% | +11.1% | +11.3% | +0.0% | -9.8% | -3.3% | -5.1% | +0.0% | -5.5% | +3.4% | +0.0% |
Range$47.00M – $61.00M
CAGR+1.2%
Avg YoY Growth+2.7%
Median YoY Growth+0.0%
R&D at Other Companies
Frequently Asked Questions
- What is Xylem's r&d?
- Xylem (XYL) reported r&d of $56.00M in Q1 2026.
- How has Xylem's r&d changed year-over-year?
- Xylem's r&d decreased by 0.0% year-over-year, from $56.00M to $56.00M.
- What is the long-term trend for Xylem's r&d?
- Over 4 years (2021 to 2025), Xylem's r&d has grown at a 2.6% compound annual growth rate (CAGR), from $204.00M to $226.00M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.